Compare BEEM & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BEEM | GBIO |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.8M | 35.4M |
| IPO Year | N/A | 2020 |
| Metric | BEEM | GBIO |
|---|---|---|
| Price | $1.72 | $5.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | $4.00 | ★ $10.67 |
| AVG Volume (30 Days) | ★ 234.3K | 40.1K |
| Earning Date | 11-14-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,668,000.00 | $15,270,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $45.61 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.33 | $3.00 |
| 52 Week High | $4.04 | $13.00 |
| Indicator | BEEM | GBIO |
|---|---|---|
| Relative Strength Index (RSI) | 37.50 | 50.63 |
| Support Level | $1.81 | $5.22 |
| Resistance Level | $2.00 | $5.64 |
| Average True Range (ATR) | 0.12 | 0.24 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 19.44 | 59.32 |
Beam Global produces sustainable technology for electric vehicle (EV) charging, outdoor media, and energy security, without the construction, disruption, and costs of grid-tied solutions. Its products are founded upon its patented EV ARC and Solar Treelines and include BeamTrak patented solar tracking, and ARC Technology energy storage, along with EV charging, outdoor media, and disaster preparedness packages. From start to finish, the company develops, patents, designs, engineers, and manufactures renewably energized products that help the environment, empower communities, and keep people moving.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.